Suppression of transforming growth factor β receptor 2 and smad5 is associated with high levels of microRNA miR-155 in the oral mucosa during chronic simian immunodeficiency virus infection

Journal of Virology

Volumn 89, Issue 5, 2015, Pages 2972-2978

  George, Jeffy ^a   Lewis, Mark G ^b   Renne, Rolf ^c   Mattapallil, Joseph J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BIOQUAL INC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MICRORNA 155; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; MICRORNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUTH MUCOSA; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SMAD5 GENE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2 GENE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; OROPHARYNX; PATHOLOGY; PHYSIOLOGY; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; MACACA MULATTA; MICRORNAS; MOUTH MUCOSA; OROPHARYNX; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SMAD5 PROTEIN;

EID: 84923035255     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03248-14     Document Type: Article

References (46)

1. Douek DC, Picker LJ, Koup RA. 2003. T cell dynamics in HIV-1 infection. Annu Rev Immunol 21:265-304. http://dx.doi.org/10.1146/annurev.immunol.21.120601.141053.
2. Douek DC, Roederer M, Koup RA. 2009. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60:471-484. http://dx.doi.org/10.1146/annurev.med.60.041807.123549.
3. Albandar JM. 2014. Aggressive and acute periodontal diseases. Periodontol 2000 65:7-12. http://dx.doi.org/10.1111/prd.12013.
4. Gonçalves LS, Gonçalves BM, Fontes TV. 2013. Periodontal disease in HIV-infected adults in the HAART era: clinical, immunological, and microbiological aspects. Arch Oral Biol 58:1385-1396. http://dx.doi.org/10.1016/j.archoralbio.2013.05.002.
5. Kroidl A, Schaeben A, Oette M, Wettstein M, Herfordt A, Haussinger D. 2005. Prevalence of oral lesions and periodontal diseases in HIVinfected patients on antiretroviral therapy. Eur J Med Res 10:448-453.
6. Mataftsi M, Skoura L, Sakellari D. 2011. HIV infection and periodontal diseases: an overview of the post-HAART era. Oral Dis 17:13-25. http://dx.doi.org/10.1111/j.1601-0825.2010.01727.x.
7. Almeida Elia CS, Etchebehere Renata M, Miranzi Benito AS, Santos Vitorino M, Reis Maria G. 2013. Oral epithelial changes in HIV-positive individuals. Pathol Res Pract 209:399-403. http://dx.doi.org/10.1016/j.prp.2013.03.001.
8. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. 1990. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 76:2303-2310.
9. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O. 1990. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 144:480-484.
10. Rautonen J, Rautonen N, Martin NL, Philip R, Wara DW. 1991. Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS 5:1319-1325. http://dx.doi.org/10.1097/00002030-199111000-00006.
11. Palladino MA, Morris RE, Starnes HF, Levinson AD. 1990. The transforming growth factor-betas. A new family of immunoregulatory molecules. Ann N Y Acad Sci 593:181-187. http://dx.doi.org/10.1111/j.1749-6632.1990.tb16110.x.
12. Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UE, Mergenhagen SE, Orenstein JM. 1991. Macrophage-and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 173:981-991. http://dx.doi.org/10.1084/jem.173.4.981.
13. Tsunawaki S, Sporn M, Ding A, Nathan C. 1988. Deactivation of macrophages by transforming growth factor-beta. Nature 334:260-262. http://dx.doi.org/10.1038/334260a0.
14. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163:1037-1050. http://dx.doi.org/10.1084/jem.163.5.1037.
15. Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, Ellingsworth L, Schmidt JA, Hall G, Roberts AB. 1988. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140: 3026-3032.
16. Allen JB, Wong HL, Guyre PM, Simon GL, Wahl SM. 1991. Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest 87:1773-1779. http://dx.doi.org/10.1172/JCI115196.
17. Havlir DV, Torriani FJ, Schrier RD, Huang JY, Lederman MM, Chervenak KA, Boom WH. 2001. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol 39:298-303. http://dx.doi.org/10.1128/JCM.39.1.298-303.2001.
18. Kekow J, Wachsman W, McCutchan JA, Cronin M, Carson DA, Lotz M. 1990. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 87:8321-8325. http://dx.doi.org/10.1073/pnas.87.21.8321.
19. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-Mavoungou V, Rouquet P, Estaquier J, Mortara L, Desoutter JF, Butor C, Le Grand R, Roques P, Simon F, Barré-Sinoussi F, Diop OM, Müller-Trutwin MC. 2005. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 115:1082-1091. http://dx.doi.org/10.1172/JCI200523006.
20. Ploquin MJ, Desoutter JF, Santos PR, Pandrea I, Diop OM, Hosmalin A, Butor C, Barre-Sinoussi F, Muller-Trutwin MC. 2006. Distinct expression profiles of TGF-beta1 signaling mediators in pathogenic SIVmac and non-pathogenic SIVagm infections. Retrovirology 3:37. http://dx.doi.org/10.1186/1742-4690-3-37.
21. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massague J. 1987. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48:409-415. http://dx.doi.org/10.1016/0092-8674(87)90192-9.
22. Laiho M, Weis MB, Massague J. 1990. Concomitant loss of transforming growth factor (TGF)-beta receptor types I and II in TGF-beta-resistant cell mutants implicates both receptor types in signal transduction. J Biol Chem 265:18518-18524.
23. Moustakas A, Souchelnytskyi S, Heldin CH. 2001. Smad regulation in TGF-beta signal transduction. J Cell Sci 114:4359-4369.
24. Kumar A, Rogers T, Maizel A, Sharma S. 1991. Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBVtransformed human B cells. J Immunol 147:998-1006.
25. Bixler SL, Sandler NG, Douek DC, Mattapallil JJ. 17 April 2013. Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection. J Virol http://dx.doi.org/10.1128/JVI.00600-13.
26. Eberly MD, Kader M, Hassan W, Rogers KA, Zhou J, Mueller YM, Mattapallil MJ, Piatak M, Jr, Lifson JD, Katsikis PD, Roederer M, Villinger F, Mattapallil JJ. 2009. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol 182:1439-1448. http://dx.doi.org/10.4049/jimmunol.182.3.1439.
27. George J, Cofano EB, Lybarger E, Louder M, Lafont BA, Mascola JR, Robert-Guroff M, Mattapallil JJ. 2011. Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. AIDS Res Hum Retroviruses 27:763-775. http://dx.doi.org/10.1089/aid.2010.0251.
28. Kader M, Hassan WM, Eberly M, Piatak M, Lifson JD, Roederer M, Mattapallil JJ. 2008. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection. J Virol 82:11467-11471. http://dx.doi.org/10.1128/JVI.01143-08.
29. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ. 2009. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2:439-449. http://dx.doi.org/10.1038/mi.2009.90.
30. Onabajo OO, George J, Lewis MG, Mattapallil JJ. 2013. Rhesus macaque lymph node PD-1(hi)CD4(+) T cells express high levels of CXCR5 and IL-21 and display a CCR7(lo)ICOS(+)Bcl6(+) T-follicular helper (Tfh) cell phenotype. PLoS One 8:e59758. http://dx.doi.org/10.1371/journal.pone.0059758.
31. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34:303-312. http://dx.doi.org/10.1111/j.1600-0684.2005.00128.x.
32. Misener S, Krawtez SA (ed). 2000. Primer3 on the WWW for general users and biologist programmers. Humana Press, Totowa, NJ.
33. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108. http://dx.doi.org/10.1038/nprot.2008.73.
34. Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington EK. 2008. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol 82:5295-5306. http://dx.doi.org/10.1128/JVI.02380-07.
35. Yin Q, Wang X, Fewell C, Cameron J, Zhu H, Baddoo M, Lin Z, Flemington EK. 2010. MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol 84:6318-6327. http://dx.doi.org/10.1128/JVI.00635-10.
36. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10:111-122. http://dx.doi.org/10.1038/nri2708.
37. Xiao C, Rajewsky K. 2009. MicroRNA control in the immune system: basic principles. Cell 136:26-36. http://dx.doi.org/10.1016/j.cell.2008.12.027.
38. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604-1609. http://dx.doi.org/10.1073/pnas.0610731104.
39. Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486. http://dx.doi.org/10.1073/pnas.0605298103.
40. Billeter AT, Hellmann J, Roberts H, Druen D, Gardner SA, Sarojini H, Galandiuk S, Chien S, Bhatnagar A, Spite M, and Polk HC, Jr. 17 September 2014, posting date. MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production. FASEB J http://dx.doi.org/10.1096/fj.14-258335.
41. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316:608-611. http://dx.doi.org/10.1126/science.1139253.
42. Haasch D, Chen YW, Reilly RM, Chiou XG, Koterski S, Smith ML, Kroeger P, McWeeny K, Halbert DN, Mollison KW, Djuric SW, Trevilmilyan JM. 2002. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol 217:78-86. http://dx.doi.org/10.1016/S0008-8749(02)00506-3.
43. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. 2007. Regulation of the germinal center response by microRNA-155. Science 316:604-608. http://dx.doi.org/10.1126/science.1141229.
44. Bignami F, Pilotti E, Bertoncelli L, Ronzi P, Gulli M, Marmiroli N, Magnani G, Pinti M, Lopalco L, Mussini C, Ruotolo R, Galli M, Cossarizza A, Casoli C. 2012. Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood 119:6259-6267. http://dx.doi.org/10.1182/blood-2011-09-379503.
45. Seddiki N, Swaminathan S, Phetsouphanh C, Kelleher AD. 2012. miR-155 is differentially expressed in Treg subsets, which may explain expression level differences of miR-155 in HIV-1 infected patients. Blood 119: 6396-6397. http://dx.doi.org/10.1182/blood-2012-02-412874.
46. Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R. 2007. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol 81:12836-12845. http://dx.doi.org/10.1128/JVI.01804-07.